AstraZeneca/$AZN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
$AZN
Sector
Primary listing
Employees
94,300
Headquarters
Website
AstraZeneca Metrics
BasicAdvanced
$264B
16.07
$5.31
0.15
$1.54
1.18%
Price and volume
Market cap
$264B
Beta
0.15
52-week high
$85.50
52-week low
$61.24
Average daily volume
4.5M
Dividend rate
$1.54
Financial strength
Current ratio
0.863
Quick ratio
0.664
Long term debt to equity
57.992
Total debt to equity
73.508
Dividend payout ratio (TTM)
59.51%
Interest coverage (TTM)
10.77%
Profitability
EBITDA (TTM)
19,128
Gross margin (TTM)
82.26%
Net profit margin (TTM)
14.68%
Operating margin (TTM)
25.40%
Effective tax rate (TTM)
17.17%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
8.28%
Return on equity (TTM)
19.67%
Valuation
Price to earnings (TTM)
16.071
Price to revenue (TTM)
2.341
Price to book
4.38
Price to tangible book (TTM)
-13.59
Price to free cash flow (TTM)
15.885
Free cash flow yield (TTM)
6.30%
Free cash flow per share (TTM)
5.371
Dividend yield (TTM)
1.80%
Forward dividend yield
1.18%
Growth
Revenue change (TTM)
15.00%
Earnings per share change (TTM)
28.86%
3-year revenue growth (CAGR)
8.66%
10-year revenue growth (CAGR)
8.20%
3-year earnings per share growth (CAGR)
86.70%
10-year earnings per share growth (CAGR)
18.97%
3-year dividend per share growth (CAGR)
2.58%
10-year dividend per share growth (CAGR)
1.12%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Bulls say / Bears say
AstraZeneca’s second-quarter 2025 revenue rose 11% year-on-year to $14.46 billion, with core EPS of $2.17 per share both surpassing analyst expectations and leading the company to reaffirm its full-year guidance. (Reuters)
The company’s oncology portfolio, representing nearly half of total revenue, grew 18% to $6.31 billion, driven by strong demand for Tagrisso, Lynparza, and Imfinzi, underscoring the strength of its core therapeutic area. (Reuters)
AstraZeneca plans to file for regulatory approval of its novel hypertension drug Baxdrostat by year-end 2025, targeting 2026 U.S. and EU approvals and anticipating peak annual sales exceeding $5 billion, diversifying its portfolio beyond oncology. (Reuters)
CEO Pascal Soriot noted the company’s proposals to cut U.S. drug prices and looming threats of tariffs and Most Favoured Nation pricing under the Trump administration underscore persistent pricing and trade uncertainties that could compress margins. (Reuters)
A unit of AstraZeneca faces a proposed class action accusing it of maintaining a Soliris monopoly through fraudulently obtained patents, alleging billions in overcharges to payers and exposing the firm to significant litigation risk. (Bloomberg Law)
AstraZeneca has postponed the Phase III AVANZAR lung cancer trial readout to the first half of 2026, potentially delaying revenue contributions from this key program. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
AstraZeneca News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of $264B as of October 06, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 16.07 as of October 06, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of October 06, 2025, the dividend rate is $1.535 and the yield is 1.18%. AstraZeneca has a payout ratio of 59.51% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.